Long-term Assessment of Motor Function and Biomarker Associations in Adults with Treated Spinal Muscular Atrophy
Overview
Revise to emphasize the implications of motor score changes and biomarker associations.
Background
Spinal muscular atrophy (SMA) is a severe neuromuscular disorder characterized by motor neuron degeneration, leading to significant disability and reduced quality of life. Recent advancements in disease-modifying therapies have transformed the management of SMA, yet the long-term outcomes and effective monitoring strategies in adults remain inadequately defined. Understanding the clinical trajectories and identifying accessible biomarkers are crucial for optimizing patient care.
Data Highlights
No numerical data available.
Key Findings
Higher SMN2 copy number correlates with later onset and milder disease severity.
Motor scores improved or stabilized during the first year of treatment, followed by a plateau or decline in some patients.
Vital capacity (%VC) was independently associated with motor function as measured by RULM.
Ulnar CMAP amplitude and creatine kinase (CK) levels were identified as potential biomarkers for predicting motor status.
Baseline features did not reliably predict short-term motor changes.
Clinical Implications
Clinicians should consider incorporating simple clinical measures such as %VC, CK, and ulnar CMAP amplitude into routine monitoring of adults with SMA. These biomarkers may provide valuable insights into motor function and treatment response, although predicting individual treatment responsiveness remains challenging.
Conclusion
The study highlights the importance of accessible clinical measures in monitoring motor function in adults with SMA, while also emphasizing the need for further research to enhance prediction of treatment outcomes.
